TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today it raised gross proceeds of CDN $2.572 million through the first tranche of a non-brokered private placement (the “Private Placement”) of 1,469,430 units (“Units”) priced at $1.75 per unit.
